Long-acting G-CSF
ApprovedSmall molecule
Long-acting G-CSF is one of 68 small molecule programs targeting Neutropenia. It is currently in Approved.
2
Indications
3
Total Trials
0
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
836 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Femara
NovartisPhase 3
Adriamycin
PfizerPhase 3
Tecentriq
RochePhase 3
Novantrone
PfizerPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Vepesid
AAvyxa
Phase 3
Arimidex
IIstituto Clinico Humanitas
Phase 3
Chiauranib
CChipscreen Biosciences, Ltd.
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
AK104
AAkeso
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Long-acting G-CSF. EMBL-EBI & Wellcome Sanger Institute.
- [4]